Johannes Tobias Neumann,Raphael Twerenbold,Jessica Weimann,Christie M Ballantyne,Emelia J Benjamin,Simona Costanzo,James A de Lemos,Christopher R deFilippi,Augusto Di Castelnuovo,Chiara Donfrancesco,Marcus Dörr,Kai M Eggers,Gunnar Engström,Stephan B Felix,Marco M Ferrario,Ron T Gansevoort,Simona Giampaoli,Vilmantas Giedraitis,Pär Hedberg,Licia Iacoviello,Torben Jørgensen,Frank Kee,Wolfgang Koenig,Kari Kuulasmaa,Joshua R Lewis,Thiess Lorenz,Magnus N Lyngbakken,Christina Magnussen,Olle Melander,Matthias Nauck,Teemu J Niiranen,Peter M Nilsson,Michael H Olsen,Torbjorn Omland,Viktor Oskarsson,Luigi Palmieri,Anette Peters,Richard L Prince,Vazhma Qaderi,Ramachandran S Vasan,Veikko Salomaa,Susana Sans,J Gustav Smith,Stefan Söderberg,Barbara Thorand,Andrew M Tonkin,Hugh Tunstall-Pedoe,Giovanni Veronesi,Tetsu Watanabe,Masafumi Watanabe,Andreas M Zeiher,Tanja Zeller,Stefan Blankenberg,Francisco Ojeda

Abstract:Importance: Identification of individuals at high risk for atherosclerotic cardiovascular disease within the population is important to inform primary prevention strategies. Objective: To evaluate the prognostic value of routinely available cardiovascular biomarkers when added to established risk factors. Design, setting, and participants: Individual-level analysis including data on cardiovascular biomarkers from 28 general population-based cohorts from 12 countries and 4 continents with assessments by participant age. The median follow-up was 11.8 years. Exposure: Measurement of high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, N-terminal pro-B-type natriuretic peptide, B-type natriuretic peptide, or high-sensitivity C-reactive protein. Main outcomes and measures: The primary outcome was incident atherosclerotic cardiovascular disease, which included all fatal and nonfatal events. The secondary outcomes were all-cause mortality, heart failure, ischemic stroke, and myocardial infarction. Subdistribution hazard ratios (HRs) for the association of biomarkers and outcomes were calculated after adjustment for established risk factors. The additional predictive value of the biomarkers was assessed using the C statistic and reclassification analyses. Results: The analyses included 164 054 individuals (median age, 53.1 years [IQR, 42.7-62.9 years] and 52.4% were women). There were 17 211 incident atherosclerotic cardiovascular disease events. All biomarkers were significantly associated with incident atherosclerotic cardiovascular disease (subdistribution HR per 1-SD change, 1.13 [95% CI, 1.11-1.16] for high-sensitivity cardiac troponin I; 1.18 [95% CI, 1.12-1.23] for high-sensitivity cardiac troponin T; 1.21 [95% CI, 1.18-1.24] for N-terminal pro-B-type natriuretic peptide; 1.14 [95% CI, 1.08-1.22] for B-type natriuretic peptide; and 1.14 [95% CI, 1.12-1.16] for high-sensitivity C-reactive protein) and all secondary outcomes. The addition of each single biomarker to a model that included established risk factors improved the C statistic. For 10-year incident atherosclerotic cardiovascular disease in younger people (aged <65 years), the combination of high-sensitivity cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein resulted in a C statistic improvement from 0.812 (95% CI, 0.8021-0.8208) to 0.8194 (95% CI, 0.8089-0.8277). The combination of these biomarkers also improved reclassification compared with the conventional model. Improvements in risk prediction were most pronounced for the secondary outcomes of heart failure and all-cause mortality. The incremental value of biomarkers was greater in people aged 65 years or older vs younger people. Conclusions and relevance: Cardiovascular biomarkers were strongly associated with fatal and nonfatal cardiovascular events and mortality. The addition of biomarkers to established risk factors led to only a small improvement in risk prediction metrics for atherosclerotic cardiovascular disease, but was more favorable for heart failure and mortality.

Cardiac biomarkers for detection of coronary artery disease in the community

Hs-cTroponins for the prediction of recurrent cardiovascular events in patients with established CHD - A comparative analysis from the KAROLA study

Biomarkers for identification of high-risk coronary artery plaques in patients with suspected coronary artery disease

Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event

Prognostic Value of Cardiovascular Biomarkers in the Population

Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study

Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort

Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial

Risk prediction of atrial fibrillation and its complications in the community using high-sensitivity cardiac troponin I: results from the BiomarCaRE Consortium

High-sensitivity cardiac troponin T: risk stratification tool in patients with symptoms of chest discomfort

Genome-wide association study of cardiac troponin I in the general population

Multiple Cardiac Biomarkers to Improve Prediction of Cardiovascular Events: Findings from the Generation Scotland Scottish Family Health Study

High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus

Analysis of Serum Cardiac Biomarkers and Treadmill Exercise Test-Electrocardiogram for the Diagnosis of Coronary Heart Disease in Suspected Patients

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy

Cardiac troponin T associates with left ventricular function and synchrony assessed by CMR in the general population: results from the Akershus Cardiac Examination 1950 Study

A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels

Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study

Accelerometer-derived physical activity and sedentary time and cardiac biomarkers: The Maastricht Study

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

Role of Cardiac Biomarkers in Epidemiology and Risk Outcomes